 |
Indication & Dosage |
| |
| |
| Oral |
| OBESITY |
| Adult:
Initially, 10 mg daily in the morning. Re-evaluate treatment in patients whose is <2 kg in the 1st 4 wk of treatment. May increase dose to 15 mg daily. Reassess 4 wk later. Discontinue treatment if weight loss is still <2 kg. Max: 15 mg daily. |
|
| |
|
| Administration |
May be taken with or without food. |
| |
|
| Precautions |
Hypertension; narrow-angle glaucoma; seizures; history of gallstones; family history of motor or verbal tics. Should not drive or operate machinery. Mild-moderate renal impairment. History of depression. History of hypertension, coronary artery disease, congestive heart failure, arrhythmias or stroke. Monitor BP and heart rate. |
| |
|
| Adverse Drug Reactions |
Dry mouth, drowsiness, dizziness, rhinitis, depression, emotional lability, migraine, skin rash, mydriasis, insomnia, constipation, diarrhoea, peripheral oedema, menstrual disorders. |
| |
|
| Interactions |
Avoid concurrent admin with or within 2 wk of stopping MAOIs. Care should be taken with drugs that may raise BP or heart rate e.g. phenylpropanolamine, ephedrine or pseudoephedrine. Increased serum levels when used with drugs that inhibit CYP3A4 e.g. ketoconazole and erythromycin. Decreased serum levels when used with rifampicin, phenytoin, carbamazepine and phenobarbital. Increased risk of serotonin syndrome when used with serotonergics such as SSRIs, sumatriptan, lithium and pethidine. |
| |
|
|
|
